safety and survival of genetically modified white blood cells in hiv-infected twins the gemini study

Conditions: HIV

Summary: this study will consolidate under one umbrella protocol all nih studies of the safety and survival of gene-modified lymphocytes in hiv-infected twins. the major purposes of the current study are to: * place subjects from the various identical twin cell transfer/gene therapy studies on a single, more uniform schedule of visits; * examine the long-term safety of apheresis procedures in non-hiv-infected lymphocyte donor twins; * examine the long-term safety of lymphocytes in hiv-infected lymphocyte recipient twins. identical twins enrolled in nih protocols 93-i-0110, 94-i-0206, 96-hg-0051, and 97-i-0165 involving the transfer of lymphocytes for the treatment of hiv infection are eligible to continue their research participation under the current protocol, 02-i-0080. participants will not undergo any additional research procedures in this study. they will continue to take their antiretroviral therapy and will be followed at least once a year, or more often if medically indicated, with a medical history, physical examination and blood tests for routine studies and to determine the number of lymphocytes in the blood. recipient twins will also have blood levels of gene-modified lymphocytes checked. recipient twins will have some blood stored for rcr (replication competent retrovirus) testing, should it become necessary. a special virus was used to insert genes into the donated lymphocytes and, although the virus was rendered incapable of growing in the body, a theoretical risk exists that the virus could mix with other viruses and possibly begin growing or reproducing. if a participant subsequently develops medical problems, the stored blood samples can be checked for rcr to see if it may be a cause of the problem.

intramural niaid sponsored several phase i-ii studies of cell transfers during the 1990's, including gene-modified cells, in identical twins discordant for hiv infection. these studies were both novel in the field of alternative treatment strategies for hiv infection and served as early studies in the developing field of clinical gene therapy. the current protocol represents an umbrella protocol in which these early trials have been consolidated for purposes of long-term safety monitoring and long-term follow-up of gene-modified cell persistence. cell recipients as well as donors enrolled in intramural niaid twin gene marking, gene therapy and cell transfer studies have been eligible for study participation. participants are monitored for safety per a uniform standardized schedule. no gene therapy, cell transfers or other investigational therapeutic interventions occur under the auspices of this protocol.

Eligibility criteria:
* inclusion criteria: activet participation, in an niaid/ccmd/nhgri protocol involving the transfer of unmodified lymphocytes, gene-marked lymphocytes or cells containing potentially therapeutic genes in the treatment of hiv-1 infection (cell donors and recipients were eligible). ongoing follow-up with a primary medical care provider who manages the subject's hiv-related and/or other medical conditions. agree to comply with study requirements and clinical policies. able to provide informed consent. exclusion criteria: a history of gross noncompliance with prior niaid/ccmd protocol requirements that, in the opinion of the principal investigator, is likely to seriously compromise the safety or value of an individual's participation in the present protocol. refusal to follow clinical center policy on partner notification (if hiv-positive). refusal to permit research blood specimens to be stored (frozen) for potential future studies, including rcr testing will be excluded (participants who have received gene-modified cells may refuse to have specimens stored for research purposes other than rcr). any medical condition that, in the opinion of the principal investigator, would make the subject inappropriate for protocol participation (such as anemia or inadequate venous access). refusal to allow the nih research team to exchange pertinent medical information with the subjects primary medical care provider.

Keywords: gene therapy hiv immunotherapy syngeneic cells gemini study